3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
33
Ovarian Neoplasms
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Metastatic Castration-resistant Prostate Cancer
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms, Castration-Resistant
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Castration-Resistant Prostate Carcinoma
2
Xanthogranuloma, Juvenile
1
Interventions
Magnetic Resonance Spectroscopy
4
pembrolizumab
3
Trastuzumab
3
Sunitinib
3
Nivolumab
3
ulixertinib
2
tipifarnib
2
palbociclib
2
lenvatinib
2
belinostat
2
Specimen Handling
2
Sirolimus
2
Radiosurgery
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
spartalizumab
1
sargramostim
1
sapanisertib
1
romidepsin
1
relatlimab
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
olaparib
×
Genitourinary
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled